Your browser doesn't support javascript.
loading
Optimising HPV vaccination communication to adolescents: A discrete choice experiment.
Chyderiotis, Sandra; Sicsic, Jonathan; Raude, Jocelyn; Bonmarin, Isabelle; Jeanleboeuf, Florian; Le Duc Banaszuk, Anne-Sophie; Gauchet, Aurélie; Bruel, Sébastien; Michel, Morgane; Giraudeau, Bruno; Thilly, Nathalie; Mueller, Judith E.
Afiliação
  • Chyderiotis S; Unité de Recherche et d'Expertise Epidémiologie des maladies émergentes, Institut Pasteur, 25 rue du Dr Roux 75724 Paris cedex 15, France. Electronic address: sandra.chyderiotis@outlook.com.
  • Sicsic J; LIRAES (EA 4470), University of Paris, Paris, France.
  • Raude J; EHESP Rennes, Université Sorbonne Paris Cité, Paris, France; Unité des Virus Emergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207 - IHU Méditerranée Infection), Marseille, France.
  • Bonmarin I; Santé publique France, Saint-Maurice, France.
  • Jeanleboeuf F; GIMAP: groupe Immunité des Muqueuses et Agents Pathogènes, EA 3064, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; Chaire PREVacCI Prévention, Vaccination et Contrôle de l'Infection, Institut PRESAGE, Université Jean Monnet, Université de Lyon, Saint-Etienne, France.
  • Le Duc Banaszuk AS; Centre Régional de Coordination des Dépistages des cancers-Pays de la Loire, Angers, France.
  • Gauchet A; Université Grenoble Alpes, LIP/PC2S, EA 4145 Grenoble, France.
  • Bruel S; HESPER EA7425, Saint-Etienne-Lyon University, Saint-Etienne, France; CIC-INSERM 1408, University Hospital of Saint-Etienne, Saint-Etienne, France.
  • Michel M; Université de Paris, ECEVE, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôtel Dieu, URC Eco Ile-de-France/Hôpital Robert Debré, Unité d'épidémiologie clinique, Paris, France; INSERM, ECEVE, UMR 1123, Paris, France.
  • Giraudeau B; Université de Tours, Université de Nantes, INSERM, SPHERE U1246, Tours, France, INSERM CIC 1415, CHRU de Tours, Tours, France.
  • Thilly N; Université de Lorraine, APEMAC, Nancy, France; Université de Lorraine, CHRU-Nancy, Département Méthodologie, Promotion, Investigation, Nancy, France.
  • Mueller JE; Unité de Recherche et d'Expertise Epidémiologie des maladies émergentes, Institut Pasteur, 25 rue du Dr Roux 75724 Paris cedex 15, France; EHESP Rennes, Université Sorbonne Paris Cité, Paris, France.
Vaccine ; 39(29): 3916-3925, 2021 06 29.
Article em En | MEDLINE | ID: mdl-34088507
ABSTRACT

BACKGROUND:

Human Papillomavirus (HPV) vaccine coverage in France is below 30%, despite proven effectiveness against HPV infections and (pre-)cancerous cervical lesions. To optimise vaccine promotion among adolescents, we used a discrete choice experiment (DCE) to identify optimal statements regarding a vaccination programme, including vaccine characteristics.

METHODS:

Girls and boys enrolled in the last two years of five middle schools in three French regions (aged 13-15 years) participated in an in-class cross-sectional self-administered internet-based study. In ten hypothetical scenarios, participants decided for or against signing up for a school-based vaccination campaign against an unnamed disease. Scenarios included different levels of four attributes the type of vaccine-preventable disease, communication on vaccine safety, potential for indirect protection, and information on vaccine uptake among peers. One scenario was repeated with an added mention of sexual transmission.

RESULTS:

The 1,458 participating adolescents (estimated response rate 89.4%) theoretically accepted vaccination in 80.1% of scenarios. All attributes significantly impacted theoretical vaccine acceptance. Compared to a febrile respiratory disease, protection against cancer was motivating (odds ratio (OR) 1.29 [95%-CI 1.09-1.52]), but not against genital warts (OR 0.91 [0.78-1.06]). Compared to risk negation ("vaccine does not provoke serious side effects"), a reference to a positive benefit-risk balance despite a confirmed side effect was strongly dissuasive (OR 0.30 [0.24-0.36]), while reference to ongoing international pharmacovigilance without any scientifically confirmed effect was not significantly dissuasive (OR 0.86 [0.71-1.04]). The potential for indirect protection motivated acceptance among girls but not boys (potential for eliminating the disease compared to no indirect protection, OR 1.57 [1.25-1.96]). Compared to mentioning "insufficient coverage", reporting that ">80% of young people in other countries got vaccinated" motivated vaccine acceptance (OR 1.94 [1.61-2.35]). The notion of sexual transmission did not influence acceptance.

CONCLUSION:

HPV vaccine communication to adolescents can be tailored to optimise the impact of promotion efforts.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Infecções por Papillomavirus / Vacinas contra Papillomavirus Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Vaccine Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Infecções por Papillomavirus / Vacinas contra Papillomavirus Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Vaccine Ano de publicação: 2021 Tipo de documento: Article